FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders

Jenni M. Lehtonen; Saara Forsström; Emanuela Bottani; Carlo Viscomi; Olivier R. Baris; Helena Isoniemi; Krister Höckerstedt; Pia Österlund; Mikko Hurme; Juulia Jylhävä; Sirpa Leppä; Ritva Markkula; Tiina Heliö; Giuliana Mombelli; Johanna Uusimaa; Reijo Laaksonen; Hannu Laaksovirta; Mari Auranen; Massimo Zeviani; Jan Smeıtınk; Rudolf J. Wiesner; Kazuto Nakada; Pirjo Isohanni; Anu Suomalainen

doi:10.1212/wnl.0000000000003374

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

This study provides Class III evidence that elevated S-FGF21 accurately distinguishes patients with mitochondrial myopathies from patients with other conditions, and FGF21 and GDF15 mitochondrial myopathy from other myopathies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lehtonen et al. (2016) studied this question.

synapsesocial.com/papers/69d8950ede3177251abed8bb https://doi.org/10.1212/wnl.0000000000003374

View Full Paper

Ask AI

Bookmark

Share

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders

Ask about this paper

Abstract

Discussion

Cite This Study

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading